10E8.4/iMab / Bill & Melinda Gates Foundation, IAVI, TaiMed Biologics, Aaron Diamond AIDS Research Center - LARVOL DELTA

10E8.4/iMab Bispecific Antibody and VRC07-523LS Monoclonal Antibody in HIV-infected Adults (clinicaltrials.gov) - P1 | N=20 | Active, not recruiting | Sponsor: David Ho | Recruiting ➔ Active, not recruiting | Trial completion date: Feb 2026 ➔ May 2027 | Trial primary completion date: May 2025 ➔ Apr 2026

Enrollment closed • Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • CD4

10E8.4/iMab Bispecific Antibody and VRC07-523LS Monoclonal Antibody in HIV-infected Adults (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: David Ho | Trial completion date: Feb 2025 ➔ Feb 2026 | Trial primary completion date: Dec 2024 ➔ May 2025

Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • CD4

10e8.4/iMAb Bispecific Antibody for Immunoprophylaxis Against High-Dose Intravenous SHIV Exposure (CROI 2024) - "Passive intravenous provision of potent anti-HIV bispecific bNAbs is a highly promising immunoprophylaxis strategy for high-dose intravenous HIV exposure."

Human Immunodeficiency Virus • Infectious Disease • CD4 • CD8

10E8.4/iMab Bispecific Antibody and VRC07-523LS Monoclonal Antibody in HIV-infected Adults (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: David Ho | Not yet recruiting ➔ Recruiting | Phase classification: P1b ➔ P1

Enrollment open • Phase classification • Human Immunodeficiency Virus • Infectious Disease • CD4

10E8.4/iMab Bispecific Antibody and VRC07-523LS Monoclonal Antibody in HIV-infected Adults (clinicaltrials.gov) - P1b | N=20 | Not yet recruiting | Sponsor: David Ho | Initiation date: Jul 2023 ➔ Oct 2023

Trial initiation date • Human Immunodeficiency Virus • Infectious Disease • CD4

10E8.4/iMab Bispecific Antibody and VRC07-523LS Monoclonal Antibody in HIV-infected Adults (clinicaltrials.gov) - P1b | N=20 | Not yet recruiting | Sponsor: David Ho

New P1 trial • Human Immunodeficiency Virus • Infectious Disease • CD4

10E8.4/iMab Bispecific Antibody in HIV-uninfected and HIV-infected Adults (clinicaltrials.gov) - P1 | N=54 | Completed | Sponsor: David Ho | Active, not recruiting ➔ Completed | Trial completion date: Nov 2022 ➔ Mar 2022

Trial completion • Trial completion date • Human Immunodeficiency Virus • Infectious Disease • CD4

10E8.4/iMab Bispecific Antibody in HIV-uninfected and HIV-infected Adults (clinicaltrials.gov) - P1 | N=54 | Active, not recruiting | Sponsor: David Ho | Trial completion date: Aug 2022 ➔ Nov 2022

Trial completion date • Human Immunodeficiency Virus • Infectious Disease • CD4

10E8.4/iMab Bispecific Antibody in HIV-uninfected and HIV-infected Adults (clinicaltrials.gov) - P1 | N=54 | Active, not recruiting | Sponsor: David Ho | Recruiting ➔ Active, not recruiting | Trial completion date: Apr 2022 ➔ Aug 2022 | Trial primary completion date: Oct 2021 ➔ Jun 2022

Enrollment closed • Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • CD4

10E8.4/iMab Bispecific Antibody in HIV-uninfected and HIV-infected Adults (clinicaltrials.gov) - P1; N=63; Recruiting; Sponsor: David Ho; Trial completion date: Apr 2021 ➔ Apr 2022; Trial primary completion date: Oct 2020 ➔ Oct 2021

Clinical • Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease

'Biomedicine Stocks' Zhongyu AIDS drug research and development progresses TMB-355 Pingmei will be launched in Mingxia [Google translation] (Yahoo News) - "Among them, the phase III clinical trial of TMB-355 intravenous bolus is nearing completion, and the final subject screening has been completed a few days ago. It will be approved by the US FDA next summer. Clinical trials of TMB-365, a second-generation long-acting drug for the treatment of AIDS, are ongoing for AIDS patients. The mid-term results are higher than expected in terms of efficacy and sustainability...Zhongyu and the U.S. government are conducting detailed plans and consultations on the Phase II clinical trial of TMB-370/380. The second phase of clinical trials is expected to start in the fall of 2021....The sales of Zhongyu TMB-355 in Europe and the United States have been affected by the epidemic this year...it is expected that from 2021, sales will return to the previously estimated high annual growth rate of 40% and continue for several years."

Enrollment closed • New P2 trial • Sales projection • sNDA • Trial status • Human Immunodeficiency Virus